Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 21;28(1):640-660.
doi: 10.3390/curroncol28010063.

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

Grace Lassiter  1 , Cole Bergeron  2 , Ryan Guedry  2 , Julia Cucarola  2 , Adam M Kaye  3 , Elyse M Cornett  4 , Alan D Kaye  4 , Giustino Varrassi  5 , Omar Viswanath  4   6   7   8 , Ivan Urits  4   9
Affiliations
Review

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

Grace Lassiter et al. Curr Oncol. .

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is the second most common blood cancer with a characteristic and unavoidable relapse/refractory state during the course of the disease, the development of new therapeutic modalities is crucial. Belantamab mafodotin (belamaf, GSK2857916) is a first-in-class therapeutic, indicated for patients who have previously attempted four other treatments, including an anti-CD38 monoclonal antibody, a proteosome inhibitor, and an immunomodulatory agent. In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. In August 2020, the FDA granted accelerated approval as a monotherapy for relapsed or treatment-refractory multiple myeloma. The drug was also approved in the EU for this indication in late August 2020. Of note, belamaf is associated with the following adverse events: decreased platelets, corneal disease, decreased or blurred vision, anemia, infusion-related reactions, pyrexia, and fetal risk, among others. Further studies are necessary to evaluate efficacy in comparison to other standard treatment modalities and as future drugs in this class are developed.

Keywords: anti-B cell maturation antigen; antibody drug conjugate; belantamab mafodotin; chronic pain; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bird S., Boyd K. Multiple myeloma: An overview of management. Palliat. Care Soc. Pract. 2019;13 doi: 10.1177/1178224219868235. - DOI - PMC - PubMed
    1. Albagoush S.A., Azevedo A.M. Multiple Myeloma. StatPearls Publishing; Treasure Island, FL, USA: 2020. [(accessed on 13 July 2020)]. Available online: https://www.ncbi.nlm.nih.gov/books/NBK534764/
    1. Michels T.C., Petersen K.E. Multiple Myeloma: Diagnosis and Treatment. Am. Fam. Physician. 2017;95:373–383. - PubMed
    1. Cowan A.J., Allen C., Barac A., Basaleem H., Bensenor I., Curado M.P., Foreman K., Gupta R., Harvey J., Hosgood H.D., et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4:1221–1227. doi: 10.1001/jamaoncol.2018.2128. - DOI - PMC - PubMed
    1. Howlader N., Noone A.M., Krapcho M., Miller D., Bishop K., Kosary C.L. Myeloma—Cancer Stat Facts [Internet]. SEER Cancer Statistics Review, 1975–2014. [(accessed on 10 December 2020)];2017 Available online: https://seer.cancer.gov/statfacts/html/mulmy.html.

MeSH terms

Substances